Clinical Research Directory

Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: * Patients aged 19 years or older * Patients with proven or suspected diagnosis of invasive Aspergillosis or invasive Mucormycosis. * Evidence of a signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Exclusion Criteria: Patients meeting any of the following criteria will not be included in the study: * Patients with known hypersensitivity to the active substance of Isavuconazole or to any of the excipients. * Patients are ineligible as determined by the investigator, such as those with familial short QT syndrome. * Patients administrating ketoconazole, high-dose ritonavir (\>200 mg every 12 hours) or strong CYP3A4/5 inducers (e.g. rifampicin, carbamazepine, phenytoin) that cannot be discontinued before administration of Cresemba.